The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Community housing lender readies first social bonds
Finance

Community housing lender readies first social bonds

The Community Housing Funding Agency received an A+ credit rating this week.

Oliver Lewis 05 Sep 2025
Warner Bros production unit moves into red
Finance

Warner Bros production unit moves into red

The production company flags a tax issue related to the Sky TV–Discovery deal.

Victoria Young 03 Sep 2025
‘Strong applications’ for RBNZ governor role
Finance

‘Strong applications’ for RBNZ governor role

A leading professor believes the selection of the governor should be reopened.

Dileepa Fonseka 02 Sep 2025
Govt confirms $5m home threshold for golden visas
Finance

Govt confirms $5m home threshold for golden visas

Latest shake-up of foreign investment announced. 

Staff reporters 01 Sep 2025